^
    19h
    COMPEL: A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P3, N=98, Active, not recruiting, AstraZeneca | Trial completion date: Jun 2026 --> Jun 2027
    Trial completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M
    |
    cisplatin • Tagrisso (osimertinib) • carboplatin • pemetrexed
    23h
    ML41701: A Phase II Study of Atezolizumab in Combination With Bevacizumab, Carboplatin or Cisplatin, and Pemetrexed for EGFR-mutant Metastatic Non-small Cell Lung Cancer Patients After Failure of EGFR Tyrosine Kinase Inhibitors. (clinicaltrials.gov)
    P2, N=22, Completed, National Taiwan University Hospital | Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Feb 2026 | Trial primary completion date: Dec 2024 --> Feb 2026
    Trial completion • Trial completion date • Trial primary completion date • IO biomarker
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • EGFR L861Q • EGFR G719X • EGFR S768I
    |
    Avastin (bevacizumab) • cisplatin • Tecentriq (atezolizumab) • carboplatin • pemetrexed
    24h
    NIBCUN: Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC (clinicaltrials.gov)
    P2, N=36, Recruiting, Sun Yat-sen University | Trial completion date: Dec 2026 --> Dec 2029 | Trial primary completion date: Dec 2025 --> Dec 2029
    Trial completion date • Trial primary completion date
    |
    Avastin (bevacizumab) • carboplatin • Tyvyt (sintilimab) • pemetrexed
    1d
    Systemic AL (λ) Amyloidosis Discovered After Neoadjuvant Pembrolizumab-Based Chemoimmunotherapy for Resectable NSCLC: Case Report. (PubMed, Respirol Case Rep)
    We report a 69-year-old man with resectable stage IIB right upper lobe lung adenocarcinoma who received neoadjuvant pembrolizumab, carboplatin, and pemetrexed followed by robotic-assisted lobectomy. He received adjuvant pembrolizumab and daratumumab-CyBorD with partial hematologic response. This case highlighted that amyloid can unexpectedly be a second diagnosis after post-neoadjuvant lung resections and that proteomic subtyping is essential for prompt haematologic staging and treatment.
    Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • PTPRT (Protein tyrosine phosphatase receptor type T)
    |
    TP53 mutation • TMB-H
    |
    Keytruda (pembrolizumab) • carboplatin • pemetrexed • Darzalex (daratumumab)
    2d
    Iparomlimab and Tuvonralimab Plus Chemotherapy Before Surgery for Stage III Lung Cancer (clinicaltrials.gov)
    P=N/A, N=28, Not yet recruiting, Tang-Du Hospital
    New trial
    |
    carboplatin • albumin-bound paclitaxel • pemetrexed • Qibeian (iparomlimab/tuvonralimab)
    2d
    Evaluate the Safety and Efficacy of BLEX 404 Oral Liquid Combined With Pemetrexed + Cisplatin Therapy (clinicaltrials.gov)
    P1/2, N=32, Not yet recruiting, Rgene Corporation | Trial completion date: Dec 2027 --> Dec 2028
    Trial completion date
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR mutation • EGFR wild-type
    |
    cisplatin • pemetrexed
    2d
    A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation. (clinicaltrials.gov)
    P1, N=330, Recruiting, Pfizer | Trial completion date: Sep 2028 --> Jan 2029 | Trial primary completion date: Sep 2027 --> Jan 2028
    Trial completion date • Trial primary completion date • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    KRAS mutation • KRAS G12C • KRAS G12
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • Erbitux (cetuximab) • cisplatin • carboplatin • gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • pemetrexed • oxaliplatin • leucovorin calcium • Zumrad (sasanlimab)
    3d
    IFCT-2502: Trial assessing treatment in patients with advanced Lung Cancer and Interstitial Lung Disease (2025-522790-10-00)
    P1/2, N=108, Not yet recruiting, Intergroupe Francophone De Cancerologie Thoracique
    New P1/2 trial
    |
    IFIH1 (Interferon Induced With Helicase C Domain 1)
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • carboplatin • gemcitabine • paclitaxel • pemetrexed • vinorelbine tartrate
    3d
    Selpercatinib and the Crossover Conundrum: Potential Impact of Postprogression Therapies on Overall Survival. (PubMed, J Clin Oncol)
    The results of Study LIBRETTO-431, an ex-US multiregional, open-label, randomized, active-controlled trial of selpercatinib versus platinum-based and pemetrexed chemotherapy with or without pembrolizumab in patients with treatment-naïve advanced rearranged during transfection fusion-positive non-small cell lung cancer, highlight the challenges of interpreting OS in trials with high crossover rates and variable postprogression therapies. Trial results demonstrated a large improvement in progression-free survival with an acceptable safety profile, but were accompanied by an immature OS analysis with a hazard ratio of 1.26, favoring the chemoimmunotherapy arm. Regardless of the position of OS in the end point hierarchy, it is critical that OS analyses include prespecified plans for data collection and analytical methods to account for the potential impact of postprogression therapies on the interpretation of study results.
    Journal
    |
    RET (Ret Proto-Oncogene)
    |
    Keytruda (pembrolizumab) • Retevmo (selpercatinib) • pemetrexed
    5d
    SOHO-02: A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) (clinicaltrials.gov)
    P3, N=444, Recruiting, Bayer | N=174 --> 444
    Enrollment change
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 mutation
    |
    Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • Hyrnuo (sevabertinib)
    5d
    MK3475-A74: Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov)
    P2, N=6, Terminated, McGill University Health Centre/Research Institute of the McGill University Health Centre | N=44 --> 6 | Trial completion date: Dec 2025 --> Apr 2026 | Recruiting --> Terminated | Trial primary completion date: Aug 2025 --> Apr 2026; Study was terminated due to low recruitment.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    Keytruda (pembrolizumab) • carboplatin • paclitaxel • pemetrexed
    6d
    Autoimmune Encephalitis Associated with Anti-titin Antibodies following Immune Checkpoint Inhibitor Therapy: A Case Report. (PubMed, Intern Med)
    We present the case of a 74-year-old man with Stage IVB lung adenocarcinoma who developed changes in his psychiatric symptoms following three cycles of treatment with cisplatin, pemetrexed, and pembrolizumab. This is the first documented case of anti-titin antibody-positive encephalitis in a patient with non-small cell lung cancer (NSCLC). This case highlights the importance of considering immune-mediated neurological complications during Immune Checkpoint Inhibitor (ICI) treatment and the value of early antibody detection and prompt immunosuppressive therapy.
    Journal • Checkpoint inhibition
    |
    TTN (Titin)
    |
    Keytruda (pembrolizumab) • cisplatin • pemetrexed